Skip to main content

Legacy Programs

Bentrio® Nasal Spray

Bentrio® is a nasal spray intended for self-protection against airborne allergens and, where approved, against airborne viruses. It has a triple protective effect:
  • By applying a thin protective layer on the nasal mucosa, a physical barrier is established that prevents inhaled particles from contacting the nasal epithelium
  • By trapping inhaled particles which are then cleared naturally with mucus from the nasal cavities into the throat and eliminated via the digestive tract
  • By humidifying the nasal mucosa and thus aiding its functionality

Physical Rather than Drug Effects

Bentrio® does not contain any active pharmaceutical ingredient; its effects are of purely physical nature. Importantly, Bentrio® does not contain any preservatives, either. Commonly used preservatives in nasal sprays are well known to harm mucosal membranes and may provoke a stinging or burning sensation. We are using a special preservative free nasal spray pump and employing a specific manufacturing process to ensure that the product is safe for use.

Extended Protection

Even the best nasal spray is not of much help if it gets cleared rapidly from the nose and needs to be reapplied frequently. Bentrio® is formulated in a gel emulsion that allows the spray to remain within the nasal cavity longer than normal liquid-based sprays, providing protection for 3-4 hours. The gel emulsion needs to be briefly shaken prior to use, making it liquid and suitable for spraying. Once it is applied into the nose, the liquid turns into a gel again. This effect is called “thixotropy”.

Overview of Key Studies

StudyStudy designStatus
SARS-CoV-2 protection in human nasal epithelium model with original virus and Delta and Omicron variants

Daily treatment with Bentrio® for 4 days starting 10 minutes prior to inoculation

Completed
SARS-CoV-2 treatment in human nasal epithelium model with original virus, and Delta and Omicron variants

Daily treatment with Bentrio® for 4 days starting 24 or 30 hours after inoculation (for original virus) and 24 hours after inoculation (for Delta and Omicron)

Completed
Prevention / treatment of H1N1 infection in human nasal epithelium model

Daily treatment with Bentrio® for 4 days starting 10 min prior to inoculation (prevention) or 24 hours after inoculation (treatment)

Completed
Prevention / treatment of HRV infection in human nasal epithelium model

Daily treatment with Bentrio® for 4 days starting 10 min prior to inoculation (prevention) or 12 hours after inoculation (treatment)

Completed
Protection against symptoms of allergic rhinitis under grass pollen challenge

Exposure of patients with history of allergic rhinitis to grass pollen for four hours, treated prior with either Bentrio® or HPMC powder nasal spray (n=36)

Completed
Assessment of the nasal residence time

Single exposure of healthy volunteers with fluoresceine stained Bentrio® or control (n=12)

Completed
Protection against symptoms of allergic rhinitis under house dust mite (HDM) exposure

Exposure of patients with history of perennial allergic rhinitis to house dust mite allergen for 3 hours, treated prior with 1 spray or 2 sprays of Bentrio® per nostril or without treatment (n=36)

Completed
Treatment of SARS-CoV-2 - COVAMID trial

Treatment of patients with confirmed Covid-19 with Bentrio®, placebo or no treatment (n=174)

Completed
Protection against symptoms of seasonal allergic rhinitis (SAR) - NASAR trial

SAR patients to self-administer Bentrio® or saline control 3 times a day or, as needed, for 2 weeks (n=100)

Completed

For further information, please visit www.bentrio.com.